Citi analyst Patrick Donnelly lowered the firm’s price target on Icon (ICLR) to $120 from $200 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Citi sees room for upside to the Q1 outlooks if biopharma activity continues to improve. The firm named Agilent its top tools pick, Natera its top diagnostics pick, and Charles River its top contract research organization pick.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
- ICON plc options imply 4.1% move in share price post-earnings
- Icon price target lowered to $120 from $200 at Barclays
- Icon plc: Valuation Overhang and Revenue Timing Issues Create Compelling Buy‑Rated Risk‑Reward Opportunity
- Icon upgraded to Buy from Hold at Jefferies
- Icon Plc (ICLR) Q4 Earnings Cheat Sheet